Drugs / DFD-29
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05343455 | Mar 2022 → Jun 2023 | rosacea | Journey Medical Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DFD-29 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05343455 ↗ |
| Route | Oral | “Participants were randomized 3:3:2 to oral DFD-29 (minocycline hydrochloride capsules), 40 mg; doxycycline, 40 mg; or placebo once daily for 16 weeks.” PMID 40042869 ↗ May 2025 |